Thomas John

Credit Name
Thomas John
Full Name
John, Thomas
 
Variants
John, Tom
 
 
Personal Site
https://www.onjcancercentre.org/profile/a-prof.-tom-john
 
Loading... 2 0 20 0 false
Loading... 3 0 20 0 false

Publications

Refined By:
Type:  Journal Article
Subject:  PD-L1

Results 1-6 of 6 (Search time: 0.012 seconds).

Publication YearTitleAuthor(s)
19-Oct-2019Brief Report: Programmed Cell Death Ligand 1 Expression in Untreated EGFR Mutated Advanced Non-Small Cell Lung Cancer and Response to Osimertinib versus Comparator in FLAURA.Brown, Helen; Vansteenkiste, Johan; Nakagawa, Kazuhiko; Cobo, Manuel; John, Thomas ; Barker, Craig; Kohlmann, Alexander; Todd, Alexander; Saggese, Matilde; Chmielecki, Juliann; Markovets, Aleksandra; Scott, Marietta; Ramalingam, Suresh S
22018Mismatch repair protein defects and microsatellite instability in malignant pleural mesothelioma.Arulananda, Surein; Thapa, Bibhusal ; Walkiewicz, Marzena; Zapparoli, Giada V; Williams, David S ; Dobrovic, Alexander ; John, Thomas 
326-Sep-2017Promoter hypomethylation of NY-ESO-1, association with clinicopathological features and PD-L1 expression in non-small cell lung cancer.Chüeh, Anderly C; Liew, Mun-Sem; Russell, Prudence A; Walkiewicz, Marzena; Jayachandran, Aparna; Starmans, Maud H W; Boutros, Paul C; Wright, Gavin; Barnett, Stephen A ; Mariadason, John M ; John, Thomas 
42017The Immune Microenvironment, Genome-wide Copy Number Aberrations, and Survival in Mesothelioma.Thapa, Bibhusal ; Salcedo, Adriana; Lin, Xihui; Walkiewicz, Marzena; Murone, Carmel ; Ameratunga, Malaka; Asadi, Khashayar ; Deb, Siddhartha; Barnett, Stephen A ; Knight, Simon; Mitchell, Paul L R ; Watkins, D Neil; Boutros, Paul C; John, Thomas 
56-Oct-2016Immunotherapy for malignant mesothelioma: reality checkThapa, Bibhusal ; Watkins, D Neil; John, Thomas 
61-Apr-2015Role of immunotherapy in lung cancer: Preliminary results of new vaccines and immune checkpoint inhibitors.John, Thomas